Stocktoria

Penumbra Inc PEN

NYSE · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2015-09-18 · LEI

Penumbra Inc (PEN) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $1.4B at a 12.7% net margin.

Chart by TradingView
75/100
Stocktoria Quality Score · grade A
6/9
Piotroski F — financial health
8.59
Altman Z″ — distress risk · safe
Dividend yield · no dividend
-2.45
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
3 5 6 4 1 5 1 7 4 6 2016201720182019202020212022202320242025
Altman Z″
11.51 10.09 9.23 7.26 7.56 6.47 5.88 7.10 6.72 8.59 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$326.58 as of 2026-08-01 · +19.8% 1y
$227.37$358.1752-wk

Beneish M-score: -2.45 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$12.5B
P / E70.1×
Net margin 5y avg4.6%
Return on equity 5y avg4.3%
Beta0.7
Employees4,700

Analyst price target

$361.83 +10.8% vs last
consensus: hold · 12 analysts
target range $323.00 – $374.00 · median $374.00
1 strong buy · 2 buy · 13 hold
Recent analyst actions
DateFirmRating
2026-07-06Evercore ISI GroupOutperform (main)
2026-06-11RBC CapitalSector Perform (reit)
2026-05-07CitigroupNeutral (main)
2026-05-07Evercore ISI GroupOutperform (main)
2026-02-26Evercore ISI GroupOutperform (main)
2026-01-20RBC CapitalSector Perform (down)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Forward estimates · earnings calendar →

Forward EPS est.$6.13
Forward P / E53.3×

Consensus analyst estimates and scheduled dates — forward-looking, may change.

Smart money · insiders, last 12 months

Insiders net sold -$865,296 on the open market · 2 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 78%
Net marginstronger than 83%
Return on equitystronger than 79%
Revenue growthstronger than 77%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.566
Retained earnings / assets0.13
EBIT / assets0.104
Equity / liabilities3.579

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
PENPenumbra Inc6/98.5970.1+17.5%
HAEHAEMONETICS CORP7/92.8536.1-2%
MMSIMERIT MEDICAL SYSTEMS INC7/94.9333.3+11.8%
IARTINTEGRA LIFESCIENCES HOLDINGS CORP5/91.17+1.5%
EMBCEmbecta Corp.6/91.992.2-3.8%
TNDMTANDEM DIABETES CARE INC3/9-3.04+7.9%
INSPInspire Medical Systems, Inc.6/99.889.1+13.6%

All Manufacturing companies →

About Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

FAQ

Is PEN financially healthy?

Penumbra Inc's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does PEN pay a dividend?

No, Penumbra Inc does not currently pay a dividend.

How profitable is PEN?

In FY2025, Penumbra Inc had a net margin of 12.7% and a return on equity of 12.4%.

Is PEN overvalued or undervalued?

Penumbra Inc trades at about 72.3× trailing earnings — below its 10-year norm (10-year range 79.2×–1614.4×, median 535.0×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for PEN?

The average Wall-Street price target for Penumbra Inc is $361.83, about 10.8% above the recent price, from 12 analysts (consensus: hold).

Is PEN a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Penumbra Inc: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 70.1×. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.